STOCK TITAN

Qiagen NV - QGEN STOCK NEWS

Welcome to our dedicated news page for Qiagen NV (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Qiagen NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Qiagen NV's position in the market.

Rhea-AI Summary
QIAGEN releases QIAstat-Dx Analyzer 2.0 with Software 1.6, offering mobile access to test results, improved epidemiology dashboards, and enhanced remote system management. Over 4,000 QIAstat-Dx instruments placed globally by 2023 for reliable diagnosis of complex syndromes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
Rhea-AI Summary
QIAGEN partners with IPPA to educate on IGRA benefits for healthcare providers and support new TB screening requirements. Updated U.S. CDC guidelines mandate IGRA testing for immigrants aged 2 and older. QIAGEN to host global event before World TB Day on March 21.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
partnership
-
Rhea-AI Summary
QIAGEN N.V. files its annual report for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission, offering printed copies to shareholders free of charge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
none
Rhea-AI Summary
QIAGEN launches QIAGEN Biomedical KB-AI, a generative AI-driven knowledge base to accelerate drug discovery in the pharma and biotech industries. The new offering contains over 640 million biomedical relationships, identifying causal relationships between genes, diseases, and drugs to aid in data-driven drug discovery. QIAGEN Biomedical KB-AI complements the human-curated QIAGEN Biomedical KB-HD, offering data scientists and bioinformaticians a comprehensive knowledge graph for exploring therapeutic avenues and repurposing existing drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
AI
-
Rhea-AI Summary
QIAGEN launches QIAGEN Biomedical KB-AI, a generative AI-driven knowledge base for drug discovery, containing 640 million biomedical relationships. The company aims to empower data scientists and bioinformaticians with comprehensive knowledge graphs to enhance data-driven drug discovery processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
Rhea-AI Summary
QIAGEN achieves sustainability milestones with eco-friendly QIAwave kits receiving ACT Label and My Green Lab Platinum certification for Sample technologies lab. The company's commitment to reducing plastic packaging and greenhouse gas emissions is highlighted, along with recognition from independent rating agencies for its ESG efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
Rhea-AI Summary
QIAGEN N.V. (NYSE: QGEN) reported Q4 2023 net sales of $509 million (+2% actual rates, +1% constant exchange rates, CER) and diluted EPS of $0.42, with an adjusted diluted EPS of $0.55. The company achieved its FY 2023 outlook for at least $1.97 billion CER sales and at least $2.07 CER adj. EPS, with 8% CER sales growth in the non-COVID portfolio and 27% adj. operating income margin. The 2024 outlook includes at least $2.0 billion CER net sales and adj. diluted EPS of at least $2.10 CER, reflecting adj. operating income margin gains but significant non-operating income pressure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
earnings covid-19
-
Rhea-AI Summary
QIAGEN (QGEN) announced a partnership with Penn State University to create a shared research and education facility for microbiome sciences. The collaboration aims to address challenges and research gaps facing the microbiome and will provide QIAGEN with a site to support the development of new products. The partnership will also offer industry research and training opportunities for next-generation scientists, including an internship program for graduate students at QIAGEN laboratories in Germany. The collaboration is anchored in a shared vision for an interconnection between the health of humans, animals, and ecosystems, and aims to accelerate the careers of scientists interested in the microbiome field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
partnership
-
Rhea-AI Summary
QIAGEN N.V. announced a synthetic share repurchase plan to return up to approximately $300 million to shareholders through a direct capital repayment and a reverse stock split. The plan is expected to reduce the number of issued shares by approximately 3% and lead to a reduction of approximately 6.9 million shares. Shareholders will receive a capital repayment of $1.28 per pre-split share. The last day of trading of the pre-split shares is planned to be Monday, January 29, 2024, with the consolidated shares expected to begin trading on Tuesday, January 30, 2024. Technical details regarding settlement mechanics for shareholders holding their QIAGEN shares in brokerage accounts in the United States and in Germany and elsewhere in Europe are also provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
buyback
Rhea-AI Summary
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) plans to release results for the fourth quarter and full year 2023 on Tuesday, February 6, after 22:05 Frankfurt time. The conference call is scheduled for Wednesday, February 7, at 15:00 Frankfurt time. Investors and analysts can join the call through various options, including call back connection, dial-in by phone, and access to the audio webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
earnings
Qiagen NV

NYSE:QGEN

QGEN Rankings

QGEN Stock Data

9.52B
219.40M
0.42%
75.16%
1.49%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Netherlands
Venlo

About QGEN

qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.